+

WO1993017746A1 - Antibacterial coated medical implants - Google Patents

Antibacterial coated medical implants Download PDF

Info

Publication number
WO1993017746A1
WO1993017746A1 PCT/US1993/002019 US9302019W WO9317746A1 WO 1993017746 A1 WO1993017746 A1 WO 1993017746A1 US 9302019 W US9302019 W US 9302019W WO 9317746 A1 WO9317746 A1 WO 9317746A1
Authority
WO
WIPO (PCT)
Prior art keywords
rifampin
combination
minocycline
novobiocin
staphylococcus
Prior art date
Application number
PCT/US1993/002019
Other languages
French (fr)
Inventor
Issam I. Raad
Rabih O. Darouiche
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to DK93907260T priority Critical patent/DK0633795T3/en
Priority to JP5515924A priority patent/JP2665399B2/en
Priority to DE69330271T priority patent/DE69330271T2/en
Priority to CA002130339A priority patent/CA2130339C/en
Priority to AU37925/93A priority patent/AU664263B2/en
Priority to AT93907260T priority patent/ATE201603T1/en
Priority to EP93907260A priority patent/EP0633795B1/en
Publication of WO1993017746A1 publication Critical patent/WO1993017746A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Definitions

  • the present invention relates to indwelling medical articles, such as catheters, coated with antibiotics to inhibit bacterial growth.
  • Indwelling medical devices including vascular catheters are becoming essential in the management of hospitalized patients by providing venous access.
  • the benefit derived from these catheters as well as other types of catheters such as peritoneal catheters, cardiovascular, orthopedic and other prosthetic devices is often upset by infectious complications.
  • the most common organisms causing these infectious complications are Staphylococcus epidermidis and Staphylococcus aureus.
  • Staphylococcus epidermidis In the case of vascular catheters, these two organisms account for almost 70-80% of all infectious organisms, with Staphylococcus epidermidis being the most common organism.
  • Candida albicans a fungal agent, account for about 10- 15% of catheter infections.
  • Colonization of bacteria on the interior surfaces of the catheter or other part of the device can produce serious patient problems, including the need to remove and/or replace the implanted device and to vigorously treat secondary infective conditions.
  • a considerable amount of attention and study has been directed toward preventing such colonization by the use of antimicrobial agents, such as antibiotics, bound to the surface of the materials employed in such devices. In such attempts the objective has been to produce a sufficient bacteriostatic or bactericidal action to prevent colonization.
  • Vancomycin was thought to be the logical antibiotic to use since it is the antibiotic of choice to treat systemic staphylococcal infections, particularly methicillin resistant S. epidermidis and S. aureus.
  • vancomycin has several limitations:
  • Vancomycin has no activity on Candida albicans; its use would decrease the rate of staphylococcal device related infections at the expense of increasing the more complicated fungal superinfections.
  • This invention provides antibiotic combinations of (a) rifampin and minocycline or (b) rifampin and novobiocin for coating surfaces of indwelling medical devices.
  • Both of these antibiotic combinations are very effective in killing biofilm-associated staphylococci, particularly Staphylococcus epidermidis and Staphylococcus aureus, when applied to the surfaces of an indwelling medical device.
  • these combinations were surprisingly effective in preventing in situ microbial colonization of indwelling medical devices and were superior to medical device.
  • these combinations were surprisingly effective in preventing in situ microbial colonization of indwelling medical devices and were superior to any other antibiotic combination in killing biofilm-adherent staphylococcal organisms in situ.
  • an implantable medical device having a portion of its surfaces coated with an antibiotic combination of (a) rifampin and minocycline or (b) rifampin and novobiocin, the combination of antibiotics in an amount sufficient to inhibit growth of biofilm encased bacteria on the coated surface.
  • the antibiotic combination can be applied to the surfaces of the devices in any number of ways, including for example but not limited to, ionic binding to a surface coating, passive adsorption, or dispersion within a polymeric base material making up the surface of the device or coated on the device surfaces.
  • Rifampin is a semisynthetic derivative of rifamycin B, a macrocyclic antibiotic compound produced by the mold Streptomyces mediterranic. Rifampin inhibits bacterial DNA-dependent RNA polymerase activity and is bactericidal in nature. Rifampin is a zwitterion that is soluble in acidic aqueous solutions, is even more soluble in organic solvents, and displays exceptional diffusion through lipids. Rifampin is available in the United States from Merrill Dow Pharmaceuticals, Cincinnati, Ohio.
  • Minocycline is a semisynthetic antibiotic derived from tetracycline. It is primarily bacteriostatic and exerts its antimicrobial effect by inhibiting protein synthesis. Minocycline is commercially available as the hydrochloride salt which occurs as a yellow, crystalline powder and is soluble in water and slightly soluble in alcohol. Following reconstitution of sterile minocycline hydrochloride with sterile water for injection, solutions have a pH of 2-2.8. Minocycline is available from Lederle Laboratories Division, American Cya ⁇ amid Company, Pearl River, New York. 17746 - -
  • Novobiocin is an antibiotic obtained from cultures of Streptomyces niveus or S. spheroides. Novobiocin is usually bacteriostatic in action and appears to interfere with bacterial cell wall synthesis and inhibits bacterial protein and nucleic acid synthesis. The drug also appears to affect stability of the cell membrane by complexing with magnesium. Novobiocin sodium is freely soluble in water and alcohol. Novobiocin is available from The Upjohn Company, Kalamazoo, Michigan.
  • each antibiotic used to coat the medical device surfaces varies to some extent with the method of coating application. In general, however, the concentration of each antibiotic can range from about O.Olmg per cm 2 to about lOmg per cm 2 .
  • the medical devices which are amenable to coatings of the subject antibiotic combinations generally have surfaces composed of thermoplastic or polymeric materials such as polyethylene, Dacron, nylon, polyesters, polytetrafluoroethylene, polyurethane, latex, silicone elastomers and the like.
  • Devices with metallic surfaces are also amenable to coatings with the antibiotic combinations.
  • Such devices for example bone and joint prosthesis, can be coated by cement mixture containing the subject antibiotic compounds.
  • the antibiotics leach from the cement into the surrounding prosthesis surface environment.
  • Particular devices especially suited for application of the antibiotic combinations of this invention include intravascular, peritoneal, pleural and urological catheters; heart valves; cardiac pacemakers; vascular shunts; and orthopedic, intraocular, or penile prosthesis.
  • Various methods can be employed to coat the surfaces of medical devices with the antibiotic combination. For example, one of the simplest methods would be to flush the surfaces of the device with a solution of the antibiotic combination. Generally, coating the surfaces by a simple flushing technique would require convenient access to the implantable device. For example, catheters, are generally amenable to flushing with a solution of rifampin and minocycline or rifampin and novobiocin.
  • the effective concentration of the antibiotic would range from about 1 to 10/tg/ml for minocycline, preferably about 2 tg/ml; 1 to 10/tg/ml for rifampin, preferably about 2/tg/ml; and 1 to 10/tg/ml for novobiocin, preferably about 2/tg/ml.
  • the flushing solution would normally be composed of sterile water or sterile normal saline solutions.
  • TDMAC tridodecylmethyl ammonium chloride
  • a medical device having a polymeric surface such as polyethylene, silastic elastomers, polytetrafluoroethylene or Darcon, can be soaked in a 5% by weight solution of TDMAC for 30 minutes at room temperature, air dried, and rinsed in water to remove excess TDMAC.
  • TDMAC precoated catheters are commercially available; for example, arterial catheters coated with TDMAC are available from Cook Critical Care, Bloomington, Indiana.
  • the device carrying the adsorbed TDMAC surfactant coated can then be incubated in a solution of the antibiotic combination for one hour or so, washed in sterile water to remove unbound antibiotic and stored in a sterile package until ready for implantation.
  • the solution of antibiotic combination is composed of a concentration of O.Olmg/ml to 50mg/ml, preferably lOmg/ml of each antibiotic in an aqueous pH 7.4-7.6 buffered solution or sterile water.
  • Equal amounts of cement alone or with antibiotics were put in the lumen of catheter latex segments in a specimen plug of the Modified Robbin's Device. Twenty-four hours later, a one-liter infusate bag made of 5% dextrose in water was infected with 5ml of 10 5 to 10 8 colony forming units (CFU) per ml of slime producing Staphylococcus epidermidis or Staphylococcus aureus strains obtained from the bloodstream of patients with catheter related bacteremia. Using a peristaltic pump, the infected infusate was run for two hours at a rate of 60ml/hr through the catheter segments of the Modified Robbin's Device.
  • CFU colony forming units
  • Each catheter segment was made of 30mm 2 silicone with a lumen filled with cement. At the end of two hours, some catheter segments (control and antibiotics coated) were taken out from specimen plugs and the cement in the lumen was removed, then the surface that was exposed to the infected fluid was cultured semiquantitatively using the roll-plate technique. Other segments were left behind and flushed with saline solution for 1-4 hours, then cultured by roll- plate.
  • Electron microscopy was used to document the adherence of staphylococci and the formation of biofilm layer on the surface of control uncoated catheter segments. Leaching of antibiotics from the cement was demonstrated to occur for at least one week by determining the inhibition around disc-shaped pieces of cement placed on blood agar plates that had been inoculated with bacteria. Coating of the catheter segments with antibiotics was demonstrated by the zone of inhibition that continued to form for at least one week around the disc-shaped catheter segments (without cement) placed on agar plates that had been inoculated with bacteria.
  • vancomycin is the only approved drug currently used to treat infections with methicillin-resistant S. epidermidis and methicillin-resistant S. aureus.
  • EXAMPLE 1 the combination of minocycline and rifampicin was found to be superior than vancomycin or a combination of vancomycin and rifampin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

An implantable medical device having long lasting resistance to staphylococcal biofilm colonization is provided. Implantable medical devices such as catheters, shunts, prosthesis, pacemakers, etc. are susceptible to colonization by biofilm adherent microorganisms, especially staphylococci. While systemic staphylococcal infections are effectively treated by many antibiotics, vancomycin being the antibiotic of choice, this same bacteria when encased in biofilm adhering to indwelling medical devices is generally resistant to antibiotic treatment. By the present invention, the combination of rifampin and minocycline or the combination or rifampin and novobiocin when coated on the surfaces of implantable medical devices unexpectedly provides superior antibacterial activity against staphylococcal biofilm colonization on the coated surface of indwelling medical devices.

Description

ANTIBACTERIAL COATED MEDICAL IMPLANTS
The present invention relates to indwelling medical articles, such as catheters, coated with antibiotics to inhibit bacterial growth.
Indwelling medical devices including vascular catheters are becoming essential in the management of hospitalized patients by providing venous access. The benefit derived from these catheters as well as other types of catheters such as peritoneal catheters, cardiovascular, orthopedic and other prosthetic devices is often upset by infectious complications. The most common organisms causing these infectious complications are Staphylococcus epidermidis and Staphylococcus aureus. In the case of vascular catheters, these two organisms account for almost 70-80% of all infectious organisms, with Staphylococcus epidermidis being the most common organism. Candida albicans, a fungal agent, account for about 10- 15% of catheter infections.
Colonization of bacteria on the interior surfaces of the catheter or other part of the device can produce serious patient problems, including the need to remove and/or replace the implanted device and to vigorously treat secondary infective conditions. A considerable amount of attention and study has been directed toward preventing such colonization by the use of antimicrobial agents, such as antibiotics, bound to the surface of the materials employed in such devices. In such attempts the objective has been to produce a sufficient bacteriostatic or bactericidal action to prevent colonization.
Vancomycin was thought to be the logical antibiotic to use since it is the antibiotic of choice to treat systemic staphylococcal infections, particularly methicillin resistant S. epidermidis and S. aureus. However, vancomycin has several limitations:
(a) While several investigators have shown that vancomycin is active against nonadherent staphylococci in vitro and human tissue, it is not active against the staphylococci that adhere to foreign bodies and embed themselves in a layer of biofilm. The biofilm (slime or fibrous glycocalix) not only acts as a shield protecting the adherent staphylococci from vancomycin, but also inhibits the activity of glycopeptide antibiotics (vancomycin and teicoplanin). See e.g.
Farber et al. /. Infect. Dis. 161:37-40 (1990); and Evans et al., Antimicrob. Agents Chemother. 31:889-894 (1987).
(b) Using vancomycin prophylactically on a highly colonized surface (such as a catheter) will lead to the emergence of vancomycin resistant staphylococci, and would deprive the clinician of the only available therapeutic choice (glycopeptide antibiotics such as vancomycin and teicoplanin) should these resistant staphylococci cause bacteremia or deep seated infection.
(c) Vancomycin has no activity on Candida albicans; its use would decrease the rate of staphylococcal device related infections at the expense of increasing the more complicated fungal superinfections.
Recent investigations into catheter associated infections have shown that bacterial produced adherent biofilms promote staphylococcal and Pseudomonas tolerance to antibiotics normally effective against the same bacteria systemically or in tissue. A dramatic representation of this problem was demonstrated by the inability of tobramycin to kill Pseudomas aeruginosa cells embedded in a biofilm at antibiotic levels of greater than 50 times the minimum bactericidal concentration (MBC) for the identical strain grown in liquid suspension. Nickel et al. ,
Antimicrob. Agents Chemother. 27:619-624 (1985). Similarly, six weeks of intensive antibacterial chemotherapy with a β lactam antibiotic, to which laboratory cultures were exquisitely sensitive, failed to prevent frequent recurrences of a S. aureus bacteremia originating from an endocardial pacemaker. Direct examination of the tip of the pacemaker lead, revealed that the staphylococci
Figure imgf000005_0001
in phenomenally thick slimed enclosed biofilm which protected the bacteria from very high tissue levels of antibiotic. Subsequent in vitro studies showed the biofilm adherent bacteria were resistant to levels of antibiotics 50 to 100 times higher than the MBC needed to kill nonbiofilm encased cells of the same strain. Khoury, A.E. and Costeron J.W., "Bacterial Biofilms in Nature and Disease," Dialogues in Pediatric Urology, Vol. 14:2-5 (1991).
Although a considerable amount of attention and study has been directed toward preventing such colonization by the use of antimicrobial agents coated to indwelling medical devices, the need persists for improved means to combat bacterial colonization of such devices.
This invention provides antibiotic combinations of (a) rifampin and minocycline or (b) rifampin and novobiocin for coating surfaces of indwelling medical devices. Both of these antibiotic combinations are very effective in killing biofilm-associated staphylococci, particularly Staphylococcus epidermidis and Staphylococcus aureus, when applied to the surfaces of an indwelling medical device. In particular, these combinations were surprisingly effective in preventing in situ microbial colonization of indwelling medical devices and were superior to medical device. I particular, these combinations were surprisingly effective in preventing in situ microbial colonization of indwelling medical devices and were superior to any other antibiotic combination in killing biofilm-adherent staphylococcal organisms in situ.
In accordance with the present invention, there is provided an implantable medical device having a portion of its surfaces coated with an antibiotic combination of (a) rifampin and minocycline or (b) rifampin and novobiocin, the combination of antibiotics in an amount sufficient to inhibit growth of biofilm encased bacteria on the coated surface. The antibiotic combination can be applied to the surfaces of the devices in any number of ways, including for example but not limited to, ionic binding to a surface coating, passive adsorption, or dispersion within a polymeric base material making up the surface of the device or coated on the device surfaces.
Rifampin is a semisynthetic derivative of rifamycin B, a macrocyclic antibiotic compound produced by the mold Streptomyces mediterranic. Rifampin inhibits bacterial DNA-dependent RNA polymerase activity and is bactericidal in nature. Rifampin is a zwitterion that is soluble in acidic aqueous solutions, is even more soluble in organic solvents, and displays exceptional diffusion through lipids. Rifampin is available in the United States from Merrill Dow Pharmaceuticals, Cincinnati, Ohio.
Minocycline is a semisynthetic antibiotic derived from tetracycline. It is primarily bacteriostatic and exerts its antimicrobial effect by inhibiting protein synthesis. Minocycline is commercially available as the hydrochloride salt which occurs as a yellow, crystalline powder and is soluble in water and slightly soluble in alcohol. Following reconstitution of sterile minocycline hydrochloride with sterile water for injection, solutions have a pH of 2-2.8. Minocycline is available from Lederle Laboratories Division, American Cyaπamid Company, Pearl River, New York. 17746 - -
Novobiocin is an antibiotic obtained from cultures of Streptomyces niveus or S. spheroides. Novobiocin is usually bacteriostatic in action and appears to interfere with bacterial cell wall synthesis and inhibits bacterial protein and nucleic acid synthesis. The drug also appears to affect stability of the cell membrane by complexing with magnesium. Novobiocin sodium is freely soluble in water and alcohol. Novobiocin is available from The Upjohn Company, Kalamazoo, Michigan.
The amount of each antibiotic used to coat the medical device surfaces varies to some extent with the method of coating application. In general, however, the concentration of each antibiotic can range from about O.Olmg per cm2 to about lOmg per cm2.
The medical devices which are amenable to coatings of the subject antibiotic combinations generally have surfaces composed of thermoplastic or polymeric materials such as polyethylene, Dacron, nylon, polyesters, polytetrafluoroethylene, polyurethane, latex, silicone elastomers and the like. Devices with metallic surfaces are also amenable to coatings with the antibiotic combinations. Such devices, for example bone and joint prosthesis, can be coated by cement mixture containing the subject antibiotic compounds. During implant use, the antibiotics leach from the cement into the surrounding prosthesis surface environment. Particular devices especially suited for application of the antibiotic combinations of this invention include intravascular, peritoneal, pleural and urological catheters; heart valves; cardiac pacemakers; vascular shunts; and orthopedic, intraocular, or penile prosthesis.
Various methods can be employed to coat the surfaces of medical devices with the antibiotic combination. For example, one of the simplest methods would be to flush the surfaces of the device with a solution of the antibiotic combination. Generally, coating the surfaces by a simple flushing technique would require convenient access to the implantable device. For example, catheters, are generally amenable to flushing with a solution of rifampin and minocycline or rifampin and novobiocin. For use in flushing solutions, the effective concentration of the antibiotic would range from about 1 to 10/tg/ml for minocycline, preferably about 2 tg/ml; 1 to 10/tg/ml for rifampin, preferably about 2/tg/ml; and 1 to 10/tg/ml for novobiocin, preferably about 2/tg/ml. The flushing solution would normally be composed of sterile water or sterile normal saline solutions.
Another method of coating the devices would be to first apply or adsorb to the surface of the medical device a layer of tridodecylmethyl ammonium chloride (TDMAC) surfactant followed by a coating layer of antibiotic combination. For example, a medical device having a polymeric surface, such as polyethylene, silastic elastomers, polytetrafluoroethylene or Darcon, can be soaked in a 5% by weight solution of TDMAC for 30 minutes at room temperature, air dried, and rinsed in water to remove excess TDMAC. Alternatively, TDMAC precoated catheters are commercially available; for example, arterial catheters coated with TDMAC are available from Cook Critical Care, Bloomington, Indiana. The device carrying the adsorbed TDMAC surfactant coated can then be incubated in a solution of the antibiotic combination for one hour or so, washed in sterile water to remove unbound antibiotic and stored in a sterile package until ready for implantation. In general, the solution of antibiotic combination is composed of a concentration of O.Olmg/ml to 50mg/ml, preferably lOmg/ml of each antibiotic in an aqueous pH 7.4-7.6 buffered solution or sterile water.
Alternative processes and reagents for bonding antibiotics to surfactant coated implantable medical devices are provided in U.S. Patent Nos. 4,442,133, 4,678,660 and 4,749,585, the entire contents of which are incorporated herein by reference. A further method useful to coat the surface of medical devices with the subject antibiotic combinations involves first coating the selected surfaces with benzalkonium chloride followed by ionic bonding of the antibiotic composition. See, e.g., Solomon, D.D. and Sherertz, R.J., /. Controlled Release 6:343-352 (1987) and U.S. Patent No. 4,442,133. Other methods of coating surfaces of medical devices with antibiotics are taught in U.S. Patent No. 4,895,566 (a medical device substrate carrying a negatively charged group having a pKa of less than 6 and a cationic antibiotic bound to the negatively charged group); U.S. Patent No. 4,917,686 (antibiotics are dissolved in a swelling agent which is adsorbed into the matrix of the surface material of the medical device); U.S. Patent No. 4,107,121 (constructing the medical device with ionogenic hydrogels, which thereafter sorb or ionically bind antibiotics); U.S. Patent No. 5,013,306 (laminating an antibiotic to a polymeric surface layer of a medical device); and U.S. Patent No. 4,952,419 (applying a film of silicone oil to the surface of an implant and then contacting the silicone film bearing surface with antibiotic powders).
These and many other methods of coating antibiotics to medical devices appear in numerous patents and medical journal articles. As is evident, one of ordinary skill having benefit of this disclosure would be apprised of several different methods of coating various medical device surfaces with the subject inventive antibiotic coatings.
We coated catheter surfaces with different combinations over a two-year period and then exposed the catheter surfaces to clinical staphylococci isolates using a Modified Robbin's Device which simulates a vascular catheter. The combination that stood out was that of rifampin and minocycline. The combination of rifampin and. novobiocin also provided unexpectedly superior results in inhibiting colonization of biofilm-associated bacteria on the surface of indwelling medical devices. EXAMPLE 1
One gram of methylmethacrylate (cement) was mixed with 0.5ml of sterile H2O and one of the following:
1. 60mg of minocycline
2. 60mg of vancomycin
3. 60mg of novobiocin
4. 30mg of rifampin 5. 30mg of rifampin and 60mg of minocycline
6. 30mg of rifampin and 60mg of vancomycin
7. 30mg of rifampin and 60mg of novobiocin
Equal amounts of cement alone or with antibiotics were put in the lumen of catheter latex segments in a specimen plug of the Modified Robbin's Device. Twenty-four hours later, a one-liter infusate bag made of 5% dextrose in water was infected with 5ml of 105 to 108 colony forming units (CFU) per ml of slime producing Staphylococcus epidermidis or Staphylococcus aureus strains obtained from the bloodstream of patients with catheter related bacteremia. Using a peristaltic pump, the infected infusate was run for two hours at a rate of 60ml/hr through the catheter segments of the Modified Robbin's Device.
Each catheter segment was made of 30mm2 silicone with a lumen filled with cement. At the end of two hours, some catheter segments (control and antibiotics coated) were taken out from specimen plugs and the cement in the lumen was removed, then the surface that was exposed to the infected fluid was cultured semiquantitatively using the roll-plate technique. Other segments were left behind and flushed with saline solution for 1-4 hours, then cultured by roll- plate.
Electron microscopy was used to document the adherence of staphylococci and the formation of biofilm layer on the surface of control uncoated catheter segments. Leaching of antibiotics from the cement was demonstrated to occur for at least one week by determining the inhibition around disc-shaped pieces of cement placed on blood agar plates that had been inoculated with bacteria. Coating of the catheter segments with antibiotics was demonstrated by the zone of inhibition that continued to form for at least one week around the disc-shaped catheter segments (without cement) placed on agar plates that had been inoculated with bacteria.
These are some of the data:
Figure imgf000011_0001
These experiments were repeated several times and results were always consistent in showing the best results with the above combination.
EXAMPLE 2
To date, vancomycin is the only approved drug currently used to treat infections with methicillin-resistant S. epidermidis and methicillin-resistant S. aureus. Using the same general protocol as described in EXAMPLE 1, the combination of minocycline and rifampicin was found to be superior than vancomycin or a combination of vancomycin and rifampin. Following the exposure of catheter segments coated with different antibiotic combinations to an infusate infected with 5ml of 103 CFU/ml of slime producing S. epidermidis, the following results were obtained:
Figure imgf000012_0001
EXAMPLE 3
When all antibiotics (minocycline, novobiocin, rifampin, vancomycin) were compared alone or in combination in parallel simultaneous experiments conducted according to the protocol described in EXAMPLE 1, the following results were obtained:
Figure imgf000012_0002

Claims

The combination of minocycline and rifampin and the combination of rifampin and novobiocin fulfilled all the qualifying conditions outlined below.
1. Efficacy—minocycline and rifampin were found to be active against the most resistant clinical strains causing catheter-related sepsis isolated at our medical centers. On catheter surfaces, both the combination of rifampin and minocycline and the combination of rifampin and novobiocin were very effective in preventing staphylococcal colonization. These combinations were equally effective against adherent and free floating organisms and were superior to vancomycin alone or the combination of vancomycin and rifampin.
2. Safety-the three antibiotics, rifampin, minocycline and novobiocin, have been used independently for years orally and intravenously without any significant adverse effects.
3. Bactericidal effect-both the combination of rifampin and minocycline and the combination of rifampin and novobiocin offer a rapid bactericidal effect against organisms that tend to adhere to catheter surfaces, with significant killing occurring within four hours after exposure to infected solution.
4. Resistant organisms developed to rifampin if used alone, but the drugs, minocycline and rifampin or novobiocin and rifampin, used in combination prevented the development of resistant strains.
5. This combination of minocycline and rifampin also exhibited some activity against Candida spp. The combination of minocycline and rifampin and the combination of rifampin and novobiocin are synergistic in their killing activity against staphylococci adhering to catheter surfaces.
EXAMPLE 4
A combination of minocycline hydrochloride (Minociri™, Lederle Laboratories, Carolina, Puerto Rico) and rifampin (Rifadin™, Merrill Dow Pharmaceuticals, Cincinnati, Ohio) in a catheter flush solution was tested for stability using a formazin-standardized color-correcting Turbidimeter (Hach Ratio Turbidimeter X R, Hach Company, Loveland, CO.) Each vial of minocycline hydrochloride and rifampin was reconstituted according to label directions using sterile water for injection. For the catheter flush solution, a final concentration of 0.1 mg/mL for each drug was prepared using 0.9% Sodium Chloride Injection, USP, as the diluent. The fully-mixed catheter flush solution was sub-divided into 20ml portions placed into 30ml vials. Triplicate test solutions were stored at 37, 24 and 4*C. Aliquots were removed from each container initially and after four, eight, and 24 hours, and after three, five, and seven days and stored in two ml sterile vials at -70* C until they were analyzed. Preliminary studies showed that - 70 *C storage did not adversely affect the activity of samples.
The combination of minocycline hydrochloride and rifampin 0.1 mg/mL of each in 0.9% Sodium Chloride Injection, USP, stored at 4 and 24 'C did not result in turbidity or the development of particulates in excess of either drug separately. At 37* C, the catheter flush solution remained clear through 24 hours but in three days had developed increased turbidity that could be seen using high-intensity illumination and was measured by the turbidimeter but could not be seen in normal room light. A color change from the initial orange to a brownish-orange occurred within four hours at 37 and 24 "C and within eight hours at 4"C. Accordingly, advanced preparation of this catheter flush solution should be limited to a maximum of three days with refrigerated storage.
Numerous modifications and variations of practicing the present invention are possible in light of the above teachings and therefore fall within the scope of the following claims.
CLAIMS:
1. An implantable medical device having one or more of its surfaces coated with an antibiotic composition comprising a combination of rifampin and minocycline, said combination coated in an amount effective to inhibit the growth of Staphylococcus.
2. The device of claim 1 wherein the combination of rifampin and minocycline is ionically bound to the surfaces.
3. The device of claim 1 wherein the combination of rifampin and minocycline is passively adsorbed to the surfaces.
4. The device of claim 1 wherein the combination of rifampin and minocycline is dispersed in a polymeric base material disposed on the surfaces.
5. An implantable medical device having one or more of its surfaces coated with an antibiotic composition comprising a combination of rifampin and novobiocin, said combination coated in an amount effective to inhibit the growth of Staphylococcus.
6. The device of claim 5 wherein the combination of rifampin and novobiocin is ionically bound to the surfaces.
7. The device of claim 5 wherein the combination of rifampin and novobiocin is passively adsorbed to the surfaces.
8. The device of claim 5 wherein the combination of rifampin and novobiocin is dispersed in a polymeric base material disposed on the surfaces.
9. A method for inhibiting Staphylococcus microbial growth on surfaces of an implantable medical device comprising:
applying to a surface of the medical device a coating of an antibiotic composition comprising a combination of rifampin and minocycline in a concentration effective to inhibit Staphylococcus microbial growth on the coated surface.
10. A method for inhibiting Staphylococcus microbial growth on surfaces of an implantable medical device comprising:
applying to a surface of the medical device a coating of an antibiotic composition comprising a combination of rifampin and novobiocin in a concentration effective to inhibit Staphylococcus microbial growth on the coated surface.
11. The method of claim 9 where the Staphylococcus is Staphylococcus aureus or Staphylococcus epidermidis.
12. The method of claim 10 wherein the Staphylococcus is Staphylococcus aureus or Staphylococcus epidermidis.
PCT/US1993/002019 1992-03-11 1993-03-04 Antibacterial coated medical implants WO1993017746A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK93907260T DK0633795T3 (en) 1992-03-11 1993-03-04 Antibacterial coated medical implants
JP5515924A JP2665399B2 (en) 1992-03-11 1993-03-04 Antimicrobial-coated medical implants
DE69330271T DE69330271T2 (en) 1992-03-11 1993-03-04 ANTIBACTERIAL COATED MEDICAL IMPLANTS
CA002130339A CA2130339C (en) 1992-03-11 1993-03-04 Antibacterial coated medical implants
AU37925/93A AU664263B2 (en) 1992-03-11 1993-03-04 Antibacterial coated medical implants
AT93907260T ATE201603T1 (en) 1992-03-11 1993-03-04 ANTIBACTERIAL COATED MEDICAL IMPLANTS
EP93907260A EP0633795B1 (en) 1992-03-11 1993-03-04 Antibacterial coated medical implants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/850,197 1992-03-11
US07/850,197 US5217493A (en) 1992-03-11 1992-03-11 Antibacterial coated medical implants

Publications (1)

Publication Number Publication Date
WO1993017746A1 true WO1993017746A1 (en) 1993-09-16

Family

ID=25307528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002019 WO1993017746A1 (en) 1992-03-11 1993-03-04 Antibacterial coated medical implants

Country Status (10)

Country Link
US (1) US5217493A (en)
EP (1) EP0633795B1 (en)
JP (1) JP2665399B2 (en)
AT (1) ATE201603T1 (en)
AU (1) AU664263B2 (en)
CA (1) CA2130339C (en)
DE (1) DE69330271T2 (en)
DK (1) DK0633795T3 (en)
ES (1) ES2159520T3 (en)
WO (1) WO1993017746A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015051A1 (en) * 1995-06-05 2000-07-05 The Board Of Regents, The University Of Texas System A multipurpose anti-microbial silastic sheath system for the prevention of device-related infections
WO2003000303A1 (en) * 2001-02-02 2003-01-03 The Trustees Of Columbia University In The City Of New York Combinations of antiseptic and antibiotic agents containing medical devices
EP1860937A1 (en) * 2005-03-21 2007-12-05 Cytacoat AB An antimicrobial agent comprising a cysteine compound covalently bound to a substrate, in particular by binding through an s-s bridge via a spacer molecule
DE102012016590A1 (en) 2012-08-14 2014-02-20 Gmbu E.V., Fachsektion Dresden Bacteria-repellent coating for bacteria-repellent finishing of e.g. biliary stents, has material produced by dissolving or dispersing cholesterol and/or cholesterol compound in fluid, and joint formed between coating and substrate materials
DE102013006185A1 (en) 2013-04-04 2014-10-09 Gmbu E.V., Fachsektion Dresden Bacteria repellent material and method of manufacture
US8906401B2 (en) 2000-12-22 2014-12-09 The Trustees Of Columbia University In The City Of New York Antimicrobial medical devices containing chlorhexidine free base and salt
DE102013013908A1 (en) 2013-08-12 2015-02-12 Gmbu E.V., Fachsektion Dresden Bacteria-repellent coating and method of manufacture
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
WO2021059780A1 (en) * 2019-09-26 2021-04-01 テルモ株式会社 Medical appliance and method for producing same

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464713B2 (en) * 1990-06-28 2002-10-15 Peter M. Bonutti Body tissue fastening
US6908466B1 (en) 1990-06-28 2005-06-21 Bonutti Ip, Llc Surgical devices having a biodegradable material with a therapeutic agent
US5489286A (en) * 1992-07-28 1996-02-06 Cinberg; James Z. Antibiotic impregnated myringotomy ventilation tube
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) * 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5514182A (en) * 1993-08-17 1996-05-07 University Of Utah Prosthetic joint with semipermeable capsule with reinforcing ribs
USH1465H (en) * 1993-09-08 1995-07-04 Medtronic, Inc. Implantable lead infection barrier
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
SE9404486D0 (en) * 1994-12-22 1994-12-22 Astra Ab catheter
US6239048B1 (en) 1994-12-28 2001-05-29 Fibermark, Inc. Light-activated antimicrobial and antiviral materials
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US6558686B1 (en) * 1995-11-08 2003-05-06 Baylor College Of Medicine Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor
SE9600276D0 (en) * 1996-01-25 1996-01-25 Astra Ab A wetting device for wetting a hydrophilic catheter and a urine collection bag incorporating said device
US6599714B1 (en) 1996-03-13 2003-07-29 University Technologies International Inc. Method of growing and analyzing a biofilm
AU716764B2 (en) * 1996-06-04 2000-03-09 Cook Incorporated Implantable medical device
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US5718717A (en) 1996-08-19 1998-02-17 Bonutti; Peter M. Suture anchor
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
DE19705579A1 (en) * 1997-02-14 1998-08-20 Huels Chemische Werke Ag An article with microorganism repellent coating, its preparation and use
US20060166358A1 (en) * 1997-03-12 2006-07-27 University Technologies International, Inc. Biofilm incubation
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6416546B1 (en) 1997-06-04 2002-07-09 Unitika Ltd. Medical device and production method thereof
US5980928A (en) * 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US20050216059A1 (en) 2002-09-05 2005-09-29 Bonutti Peter M Method and apparatus for securing a suture
WO1999009997A1 (en) 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6045551A (en) 1998-02-06 2000-04-04 Bonutti; Peter M. Bone suture
US6273875B1 (en) 1998-08-17 2001-08-14 Edwards Lifesciences Corporation Medical devices having improved antimicrobial/antithrombogenic properties
JP4898991B2 (en) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー Sheathed medical device
US6592814B2 (en) * 1998-10-02 2003-07-15 Johnson & Johnson Vision Care, Inc. Biomedical devices with antimicrobial coatings
US6475434B1 (en) * 1998-12-07 2002-11-05 Baylor College Of Medicine Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices
US6528107B2 (en) 1999-01-19 2003-03-04 Sulzer Carbomedics Inc. Method for producing antimicrobial antithrombogenic medical devices
US20010041870A1 (en) * 1999-03-09 2001-11-15 Edward M. Gillis Implantable device for access to a treatment site
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6562295B1 (en) * 1999-06-30 2003-05-13 Ceramoptec Industries, Inc. Bacteria resistant medical devices
US6416549B1 (en) 1999-07-19 2002-07-09 Sulzer Carbomedics Inc. Antithrombogenic annuloplasty ring having a biodegradable insert
US6447516B1 (en) 1999-08-09 2002-09-10 Peter M. Bonutti Method of securing tissue
US6368343B1 (en) 2000-03-13 2002-04-09 Peter M. Bonutti Method of using ultrasonic vibration to secure body tissue
US6635073B2 (en) 2000-05-03 2003-10-21 Peter M. Bonutti Method of securing body tissue
US9138222B2 (en) 2000-03-13 2015-09-22 P Tech, Llc Method and device for securing body tissue
US7094251B2 (en) 2002-08-27 2006-08-22 Marctec, Llc. Apparatus and method for securing a suture
US8932330B2 (en) * 2000-03-13 2015-01-13 P Tech, Llc Method and device for securing body tissue
WO2001079421A2 (en) * 2000-04-17 2001-10-25 University Technologies International, Inc. Apparatus and methods for testing effects of materials and surface coatings on the formation of biofilms
US6599696B2 (en) 2000-04-17 2003-07-29 University Technologies International, Inc. Effects of materials and surface coatings on encrustation and biofilm formation
US6596505B2 (en) 2000-04-17 2003-07-22 University Technologies International, Inc. Apparatus and methods for testing effects of materials and surface coatings on the formation of biofilms
EP1303256B1 (en) * 2000-06-09 2009-01-07 Baylor College of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
UA75083C2 (en) * 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
US6534112B1 (en) * 2000-08-01 2003-03-18 Ams Research Corporation Semi-automatic coating system methods for coating medical devices
DE10114247A1 (en) * 2001-03-22 2002-10-10 Heraeus Kulzer Gmbh & Co Kg Antibiotic / antibiotics-polymer combination
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
US6589591B1 (en) * 2001-07-10 2003-07-08 Baylor College Of Medicine Method for treating medical devices using glycerol and an antimicrobial agent
US6719765B2 (en) 2001-12-03 2004-04-13 Bonutti 2003 Trust-A Magnetic suturing system and method
US6716200B2 (en) 2002-01-18 2004-04-06 C.R. Bard, Inc. Antimicrobial urine collection system and methods of manufacturing the same
US20050192547A1 (en) * 2002-01-31 2005-09-01 Modak Shanta M. Combinations of antiseptic and antibiotic agents containing medical devices
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US6887270B2 (en) * 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US9155544B2 (en) 2002-03-20 2015-10-13 P Tech, Llc Robotic systems and methods
US6968234B2 (en) * 2002-04-25 2005-11-22 Medtronic, Inc. Implantable medical device having biologically active polymeric casing
US20030208166A1 (en) * 2002-05-06 2003-11-06 Schwartz Anthony H. Implantable device with free-flowing exit and uses thereof
ATE495769T1 (en) 2002-07-12 2011-02-15 Cook Inc COATED MEDICAL DEVICE
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
DE10242476B4 (en) * 2002-09-11 2006-10-26 Heraeus Kulzer Gmbh Antibiotic / antibiotics-polymer combination
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
US6992127B2 (en) 2002-11-25 2006-01-31 Ast Products, Inc. Polymeric coatings containing a pH buffer agent
US20050079199A1 (en) * 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
WO2004084973A2 (en) 2003-03-24 2004-10-07 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US7497864B2 (en) 2003-04-30 2009-03-03 Marctec, Llc. Tissue fastener and methods for using same
US20040256561A1 (en) * 2003-06-17 2004-12-23 Allyson Beuhler Wide band light sensing pixel array
WO2005027990A2 (en) * 2003-09-15 2005-03-31 Univ Jefferson Implants with attached silylated therapeutic agents
WO2005037338A1 (en) * 2003-10-14 2005-04-28 Cook Incorporated Hydrophilic coated medical device
US20080039873A1 (en) 2004-03-09 2008-02-14 Marctec, Llc. Method and device for securing body tissue
CA2561496A1 (en) * 2004-04-02 2005-10-20 Baylor College Of Medicine Novel modification of medical prostheses
EP1793875B9 (en) * 2004-06-16 2010-09-08 Affinergy, Inc. Ifbm's to promote attachment of target analytes
US9463012B2 (en) 2004-10-26 2016-10-11 P Tech, Llc Apparatus for guiding and positioning an implant
US9173647B2 (en) 2004-10-26 2015-11-03 P Tech, Llc Tissue fixation system
US9271766B2 (en) 2004-10-26 2016-03-01 P Tech, Llc Devices and methods for stabilizing tissue and implants
US20060089646A1 (en) 2004-10-26 2006-04-27 Bonutti Peter M Devices and methods for stabilizing tissue and implants
US20090191254A1 (en) * 2004-12-06 2009-07-30 The Govt. Of The U.S.A., Centers For Disease Control And Prevention Inhibition of biofilm formation using bacteriophage
US20060126751A1 (en) * 2004-12-10 2006-06-15 Anthony Bessios Technique for disparity bounding coding in a multi-level signaling system
UA91205C2 (en) * 2004-12-17 2010-07-12 Венус Ремедиз Лимитед Antibiotic combinations for providing total solution to the treatment of infections
GB0502399D0 (en) 2005-02-05 2005-03-16 Vascutek Ltd Infection resistant medical implants
US9089323B2 (en) 2005-02-22 2015-07-28 P Tech, Llc Device and method for securing body tissue
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US20070134287A1 (en) * 2005-12-09 2007-06-14 Biomet Manufacturing Corp Method for coating biocompatible substrates with antibiotics
US7967820B2 (en) 2006-02-07 2011-06-28 P Tech, Llc. Methods and devices for trauma welding
US11253296B2 (en) 2006-02-07 2022-02-22 P Tech, Llc Methods and devices for intracorporeal bonding of implants with thermal energy
US11278331B2 (en) 2006-02-07 2022-03-22 P Tech Llc Method and devices for intracorporeal bonding of implants with thermal energy
US8496657B2 (en) 2006-02-07 2013-07-30 P Tech, Llc. Methods for utilizing vibratory energy to weld, stake and/or remove implants
EP2114298B1 (en) 2006-02-08 2022-10-19 Medtronic, Inc. Temporarily stiffened mesh prostheses
US8591531B2 (en) 2006-02-08 2013-11-26 Tyrx, Inc. Mesh pouches for implantable medical devices
US8315700B2 (en) * 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US11246638B2 (en) 2006-05-03 2022-02-15 P Tech, Llc Methods and devices for utilizing bondable materials
EP2032089B1 (en) * 2006-06-22 2011-08-31 Wilson-Cook Medical Inc. Self-cleaning stent
US8512294B2 (en) * 2006-07-28 2013-08-20 Becton, Dickinson And Company Vascular access device antimicrobial materials and solutions
US20080051911A1 (en) * 2006-08-23 2008-02-28 Wilson-Cook Medical Inc. Stent with antimicrobial drainage lumen surface
US8298564B2 (en) * 2006-09-27 2012-10-30 Medtronic, Inc. Two part antimicrobial boot
US9023114B2 (en) * 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
US8617185B2 (en) 2007-02-13 2013-12-31 P Tech, Llc. Fixation device
US8177834B2 (en) 2007-03-12 2012-05-15 Cook Medical Technologies Llc Woven fabric with shape memory element strands
US8911765B2 (en) * 2007-03-29 2014-12-16 Tyrx, Inc. Biodegradable, polymer coverings for breast implants
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
ATE551077T1 (en) * 2007-04-17 2012-04-15 Medtronic Inc REDUCING INFECTION RELATED TO A MEDICAL DEVICE
US8430852B2 (en) * 2007-04-17 2013-04-30 Medtronic, Inc. Therapeutic sleeve for implantable medical device
US8933290B2 (en) * 2007-06-26 2015-01-13 Sofradim Production Sas Mesh implant
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
US20090041727A1 (en) * 2007-08-08 2009-02-12 Conjugon, Inc. Compositions and Methods for Microbe Storage and Delivery
JP2010537743A (en) 2007-08-31 2010-12-09 ウィルソン−クック・メディカル・インコーポレーテッド Medical implant with improved drug eluting element
US20090099531A1 (en) * 2007-10-15 2009-04-16 Griesbach Iii Henry Louis Packaging for selectivity lubricating part of a medical device
US9308068B2 (en) 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
US8834552B2 (en) * 2007-12-27 2014-09-16 Cook Medical Technologies Llc Stent graft having floating yarns
US8187316B2 (en) * 2007-12-27 2012-05-29 Cook Medical Technologies Llc Implantable graft device having treated yarn and method for making same
US20090171451A1 (en) * 2007-12-27 2009-07-02 Cook Incorporated Implantable device having composite weave
WO2009156866A2 (en) 2008-06-27 2009-12-30 Sofradim Production Biosynthetic implant for soft tissue repair
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US8419793B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
US8420153B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
US8445008B2 (en) * 2008-10-17 2013-05-21 Medtronic, Inc. Reduction of infection associated with medical device
US8640643B2 (en) * 2008-12-26 2014-02-04 Ams Research Corporation Method for controlling drug loading in a medical device
US20100198278A1 (en) * 2009-02-02 2010-08-05 Medtronic, Inc. Composite antimicrobial accessory including a membrane layer and a porous layer
US20100215716A1 (en) * 2009-02-23 2010-08-26 Biomet Manufacturing Corp. Compositions and methods for coating orthopedic implants
EP2400899A4 (en) 2009-02-24 2015-03-18 P Tech Llc Methods and devices for utilizing bondable materials
US8209016B2 (en) * 2009-03-20 2012-06-26 Medtronic, Inc. Implantable lead management
WO2010107977A2 (en) 2009-03-20 2010-09-23 Board Of Regents Of The University Of Texas System Method for imparting antimicrobial activity to a medical device
US20100247600A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Therapeutic drug eluting implant cover and method of making the same
US20100249783A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Drug-eluting implant cover
US8092443B2 (en) 2009-03-30 2012-01-10 Medtronic, Inc. Element for implantation with medical device
CA2752905A1 (en) 2009-04-02 2010-10-07 Cook Medical Technologies Llc System and method for maintaining patency of a stent using a magnet
US9078712B2 (en) * 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9414864B2 (en) * 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
US8858983B2 (en) * 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
US8821455B2 (en) * 2009-07-09 2014-09-02 Becton, Dickinson And Company Antimicrobial coating for dermally invasive devices
FR2949688B1 (en) 2009-09-04 2012-08-24 Sofradim Production FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER
EP2475405B1 (en) 2009-09-09 2016-04-13 Cook Medical Technologies LLC Substrate surface modification utilizing a densified fluid and a surface modifier
US20110065798A1 (en) * 2009-09-17 2011-03-17 Becton, Dickinson And Company Anti-infective lubricant for medical devices and methods for preparing the same
EP3489313A1 (en) 2010-08-25 2019-05-29 Tyrx, Inc. Novel medical device coatings
WO2012064963A1 (en) 2010-11-12 2012-05-18 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED
EP2688605A4 (en) 2011-03-24 2014-09-10 Bard Inc C R Fixation and protection of an implanted medical device
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
FR2977789B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
US20130030243A1 (en) * 2011-07-28 2013-01-31 Boston Scientific Scimed, Inc. Anti-bacterial surgical meshes
GB201116010D0 (en) * 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
CA2849052C (en) 2011-09-30 2019-11-05 Sofradim Production Reversible stiffening of light weight mesh
US8834772B2 (en) 2011-12-07 2014-09-16 Biomet Manufacturing, Llc Antimicrobial methacrylate cements
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production KNITTED PICOTS
FR2985170B1 (en) 2011-12-29 2014-01-24 Sofradim Production PROSTHESIS FOR INGUINAL HERNIA
FR2994185B1 (en) 2012-08-02 2015-07-31 Sofradim Production PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER
DK2882433T3 (en) 2012-08-08 2019-05-27 Univ Texas ANTI-MICROBIBLE COMPOSITIONS INCLUDING GLYCERYL NITRATES
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production HEMOSTATIC PATCH AND PREPARATION METHOD
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME
US10159555B2 (en) 2012-09-28 2018-12-25 Sofradim Production Packaging for a hernia repair device
AU2013338051C1 (en) 2012-10-29 2017-08-10 Ariste Medical, Llc. Polymer coating compositions and coated products
CN109453433A (en) 2012-11-14 2019-03-12 整形外科创新中心公司 Pass through the antimicrobial article of addition manufacture production
US10076377B2 (en) 2013-01-05 2018-09-18 P Tech, Llc Fixation systems and methods
US9695323B2 (en) 2013-02-13 2017-07-04 Becton, Dickinson And Company UV curable solventless antimicrobial compositions
US9750928B2 (en) 2013-02-13 2017-09-05 Becton, Dickinson And Company Blood control IV catheter with stationary septum activator
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
US9327095B2 (en) 2013-03-11 2016-05-03 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US9750927B2 (en) 2013-03-11 2017-09-05 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
CA2906238A1 (en) * 2013-03-15 2014-09-18 Interface Biologics, Inc. Compounds and compositions for drug release
EP3777977B1 (en) 2013-04-18 2024-07-17 Board of Regents, The University of Texas System Antimicrobial catheters
FR3006581B1 (en) 2013-06-07 2016-07-22 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
FR3006578B1 (en) 2013-06-07 2015-05-29 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
US9278002B2 (en) * 2013-06-07 2016-03-08 Gregory Merrell Elbow antibiotic spacer implant
GB2528421B (en) 2014-04-22 2016-12-14 Ariste Medical Inc Methods and processes for application of drug delivery polymeric coatings
US9675793B2 (en) 2014-04-23 2017-06-13 Becton, Dickinson And Company Catheter tubing with extraluminal antimicrobial coating
US9789279B2 (en) 2014-04-23 2017-10-17 Becton, Dickinson And Company Antimicrobial obturator for use with vascular access devices
US10376686B2 (en) 2014-04-23 2019-08-13 Becton, Dickinson And Company Antimicrobial caps for medical connectors
US10232088B2 (en) 2014-07-08 2019-03-19 Becton, Dickinson And Company Antimicrobial coating forming kink resistant feature on a vascular access device
EP3000489B1 (en) 2014-09-24 2017-04-05 Sofradim Production Method for preparing an anti-adhesion barrier film
EP3000432B1 (en) 2014-09-29 2022-05-04 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
EP3000433B1 (en) 2014-09-29 2022-09-21 Sofradim Production Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis
EP3029189B1 (en) 2014-12-05 2021-08-11 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
EP3059255B1 (en) 2015-02-17 2020-05-13 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
EP3085337B1 (en) 2015-04-24 2022-09-14 Sofradim Production Prosthesis for supporting a breast structure
EP3106185B1 (en) 2015-06-19 2018-04-25 Sofradim Production Synthetic prosthesis comprising a knit and a non porous film and method for forming same
US20180289003A1 (en) * 2015-08-24 2018-10-11 Smith & Nephew, Inc. Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
US10058393B2 (en) 2015-10-21 2018-08-28 P Tech, Llc Systems and methods for navigation and visualization
US10493244B2 (en) 2015-10-28 2019-12-03 Becton, Dickinson And Company Extension tubing strain relief
EP3195830B1 (en) 2016-01-25 2020-11-18 Sofradim Production Prosthesis for hernia repair
WO2017147067A1 (en) 2016-02-22 2017-08-31 Board Of Regents, The University Of Texas System Antimicrobial compositions and uses thereof
EP3312325B1 (en) 2016-10-21 2021-09-22 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
US9999899B2 (en) 2016-11-01 2018-06-19 International Business Machines Corporation Controlled exposure of in-vivo sensors
EP3538217B1 (en) * 2016-11-14 2024-07-24 The Curators of the University of Missouri Neutron capture therapy for infection control of surgical implants
EP3554624A1 (en) 2016-12-18 2019-10-23 Cardiac Pacemakers, Inc. Infection fighting drug eluting lead boot
WO2018112355A1 (en) 2016-12-18 2018-06-21 Cardiac Pacemakers, Inc. Infection fighting drug eluting device
EP3398554A1 (en) 2017-05-02 2018-11-07 Sofradim Production Prosthesis for inguinal hernia repair
EP3740494A4 (en) 2018-02-02 2021-11-03 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
WO2020049177A1 (en) * 2018-09-06 2020-03-12 Biomodics Aps A medical tubular device
EP3653171B1 (en) 2018-11-16 2024-08-21 Sofradim Production Implants suitable for soft tissue repair
US12064330B2 (en) 2020-04-28 2024-08-20 Covidien Lp Implantable prothesis for minimally invasive hernia repair
MX2022013665A (en) 2020-05-01 2022-11-30 Ripple Therapeutics Corp HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4846844A (en) * 1987-08-31 1989-07-11 Eli Lilly And Company Antimicrobial coated implants
US4879135A (en) * 1984-07-23 1989-11-07 University Of Medicine And Dentistry Of New Jersey Drug bonded prosthesis and process for producing same
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS179567B1 (en) * 1974-11-25 1977-11-30 Vladimir Stoy Ionogennic hydrophilic in water insoluble gels based on partial saponificated polymers or copolymers acrylonitrile and method of preparing them
US4678660A (en) * 1984-12-07 1987-07-07 Deseret Medical, Inc. Thermoplastic polyurethane anticoagulant alloy coating
US4917686A (en) * 1985-12-16 1990-04-17 Colorado Biomedical, Inc. Antimicrobial device and method
US4749585A (en) * 1986-04-11 1988-06-07 University Of Medicine And Dentistry Of New Jersey Antibiotic bonded prosthesis and process for producing same
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US4915694A (en) * 1987-10-02 1990-04-10 Vitaphore Corporation Antimicrobial wound dressing and skin fixator for percutaneous conduits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879135A (en) * 1984-07-23 1989-11-07 University Of Medicine And Dentistry Of New Jersey Drug bonded prosthesis and process for producing same
US4846844A (en) * 1987-08-31 1989-07-11 Eli Lilly And Company Antimicrobial coated implants
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015051A4 (en) * 1995-06-05 2000-07-05 Univ Texas A multipurpose anti-microbial silastic sheath system for the prevention of device-related infections
EP1015051A1 (en) * 1995-06-05 2000-07-05 The Board Of Regents, The University Of Texas System A multipurpose anti-microbial silastic sheath system for the prevention of device-related infections
US8906401B2 (en) 2000-12-22 2014-12-09 The Trustees Of Columbia University In The City Of New York Antimicrobial medical devices containing chlorhexidine free base and salt
WO2003000303A1 (en) * 2001-02-02 2003-01-03 The Trustees Of Columbia University In The City Of New York Combinations of antiseptic and antibiotic agents containing medical devices
US9155301B2 (en) 2005-03-21 2015-10-13 Cytacoat Ab Antimicrobial agent comprising a cysteine component covalently bound to a substrate in particular by binding through an S-S bridge via a spacer molecule
EP1860937A1 (en) * 2005-03-21 2007-12-05 Cytacoat AB An antimicrobial agent comprising a cysteine compound covalently bound to a substrate, in particular by binding through an s-s bridge via a spacer molecule
EP1860937A4 (en) * 2005-03-21 2012-03-28 Cytacoat Ab An antimicrobial agent comprising a cysteine compound covalently bound to a substrate, in particular by binding through an s-s bridge via a spacer molecule
US8563612B2 (en) 2005-03-21 2013-10-22 Cytacoat Ab Antimicrobial agent comprising a cysteine component covalently bound to a substrate in particular by binding through an S-S bridge via a spacer molecule
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
DE102012016590A1 (en) 2012-08-14 2014-02-20 Gmbu E.V., Fachsektion Dresden Bacteria-repellent coating for bacteria-repellent finishing of e.g. biliary stents, has material produced by dissolving or dispersing cholesterol and/or cholesterol compound in fluid, and joint formed between coating and substrate materials
DE102013006185A1 (en) 2013-04-04 2014-10-09 Gmbu E.V., Fachsektion Dresden Bacteria repellent material and method of manufacture
DE102013013908A1 (en) 2013-08-12 2015-02-12 Gmbu E.V., Fachsektion Dresden Bacteria-repellent coating and method of manufacture
WO2021059780A1 (en) * 2019-09-26 2021-04-01 テルモ株式会社 Medical appliance and method for producing same

Also Published As

Publication number Publication date
DK0633795T3 (en) 2001-08-13
DE69330271T2 (en) 2001-09-27
EP0633795A1 (en) 1995-01-18
JPH07501470A (en) 1995-02-16
CA2130339A1 (en) 1993-09-16
AU3792593A (en) 1993-10-05
ATE201603T1 (en) 2001-06-15
CA2130339C (en) 2001-02-13
US5217493A (en) 1993-06-08
EP0633795A4 (en) 1995-05-24
ES2159520T3 (en) 2001-10-16
AU664263B2 (en) 1995-11-09
DE69330271D1 (en) 2001-07-05
JP2665399B2 (en) 1997-10-22
EP0633795B1 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
EP0633795B1 (en) Antibacterial coated medical implants
US5362754A (en) M-EDTA pharmaceutical preparations and uses thereof
Bayston et al. Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials.
Dunne Jr et al. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm
Kockro et al. Use of scanning electron microscopy to investigate the prophylactic efficacy of rifampin-impregnated CSF shunt catheters
JP4630238B2 (en) CATHETER, MEDICAL IMPLANT, AND METHOD FOR INJECTION THEREOF
US6224579B1 (en) Triclosan and silver compound containing medical devices
US5688516A (en) Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US9380780B2 (en) Transdermal venous access locking solutions
CA2411944C (en) The combination of antimicrobial agents and bacterial interference to coat medical devices
US5756145A (en) Durable, Resilient and effective antimicrobial coating for medical devices and method of coating therefor
US20030229401A1 (en) Method for treating medical devices using glycerol and an antimicrobial agent
US20060099237A1 (en) Antimicrobial medical articles containing a combination of anti-infective compounds, octoxyglycerin, salicylic acid, and sesquiterpenoids
WO2007003028A1 (en) Antimicrobial compositions for inhibiting growth and proliferation of a microbial biofilm on medical devices
JP5393030B2 (en) Medical device and method for manufacturing medical device
US8426044B2 (en) Method for imparting antimicrobial activity to a medical device
Jansen et al. New aspects in the pathogenesis and prevention of polymer-associated foreign-body infections caused by coagulase-negative staphylococci
WO2005018701A1 (en) Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
DK2750501T3 (en) TRANSDERMAL VENEAL ACCESS LOCK SOLUTIONS
Li et al. In vitro antimicrobial activity of a new antiseptic central venous catheter
Gilmore et al. Antimicrobial devices
CA2148942C (en) M-edta pharmaceutical preparations and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2130339

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993907260

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993907260

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993907260

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载